Vutrisiran Market Size Forecasted to Grow at 13.18% CAGR, Reaching USD 2.15 billion by 2034

March 15, 2025 02:12 PM GMT | By EIN Presswire
 Vutrisiran Market Size Forecasted to Grow at 13.18% CAGR, Reaching USD 2.15 billion by 2034
Image source: EIN Presswire

As per MRFR analysis, the Vutrisiran Market Growth Size was estimated at 0.62 (USD Billion) in 2024. US, NY, UNITED STATES, March 15, 2025 /EINPresswire.com/ -- Vutrisiran is a therapeutic agent developed for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR), a rare and progressive genetic disorder characterized by the accumulation of misfolded transthyretin (TTR) proteins, leading to amyloid fibril deposits in various tissues and organs, including the nerves, heart, and kidneys. Utilizing RNA interference (RNAi) technology, vutrisiran targets and degrades TTR mRNA in the liver, thereby reducing the production of both wild-type and mutant TTR proteins.

As per MRFR analysis, the Vutrisiran Market Growth Size was estimated at 0.62 (USD Billion) in 2024. The Vutrisiran Market Industry is expected to grow from 0.71 (USD Billion) in 2025 to 2.15 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.18% during the forecast period (2025 - 2034).

Top Vutrisiran Market Companies

MerckCo

Roche

Sanofi

AstraZeneca

Teva Pharmaceuticals

Pfizer

Ionis Pharmaceuticals

Alnylam Pharmaceuticals

Bristol Myers Squibb

Genzyme

GSK

AbbVie

Novartis

Regeneron Pharmaceuticals

Get Free Sample PDF Copy of This Report -

https://www.marketresearchfuture.com/sample_request/33305

The Vutrisiran Market is experiencing significant growth driven primarily by the increasing prevalence of hereditary transthyretin amyloidosis (hATTR) and the rising awareness regarding genetic disorders. The need for innovative therapeutic solutions that address the challenges associated with hATTR is creating a surge in demand for Vutrisiran, which offers an effective treatment option. Additionally, advancements in biotechnology and drug delivery systems are facilitating the development of targeted therapies that harness the potential of Vutrisiran, further propelling market dynamics.

𝖨𝗇𝖽𝗎𝗌𝗍𝗋𝗒 𝖣𝖾𝗍𝖺𝗂𝗅𝖾𝖽 𝖲𝖾𝗀𝗆𝖾𝗇𝗍𝖺𝗍𝗂𝗈𝗇:

Vutrisiran Market Segmentation Insights

Vutrisiran Market Product Formulation Outlook

Injectable

Oral

Vutrisiran Market Therapeutic Area Outlook

Genetic Disorders

Cardiovascular Diseases

Neurological Disorders

Vutrisiran Market Distribution Channel Outlook

Hospital pharmacies

Retail pharmacies

Online pharmacies

Vutrisiran Market Patient Demographics Outlook

Pediatric

Adult

Geriatric

Vutrisiran Market Treatment Type Outlook

Monotherapy

Combination Therapy

Vutrisiran Market Regional Outlook

North America

Europe

South America

Asia Pacific

Middle East and Africa

The Vutrisiran Market, valued at 0.49 billion USD in 2023, reveals significant insights within its Treatment Type segment, primarily encompassing Monotherapy and Combination Therapy. Most of the market growth is driven by the rising adoption of innovative treatment modalities tailored to patient needs. Monotherapy plays a crucial role, catering to patients who require targeted interventions, thereby enhancing treatment efficacy and patient adherence. In contrast, Combination Therapy is gaining traction due to its ability to address complex cases and optimize treatment outcomes by leveraging the synergistic potential of multiple therapeutics.

Buy Now –

https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=33305

Key Benefits:

Addressing Unmet Medical Needs: hATTR is a progressive disease with limited treatment options. Vutrisiran offers a novel therapeutic approach by targeting the root cause of the disease, providing hope for patients who previously had few alternatives.

Increasing Prevalence and Awareness: Improved diagnostic techniques and heightened awareness have led to an increase in the diagnosed cases of hATTR. This expansion of the patient pool has contributed to the growing demand for effective treatments like vutrisiran.

Regulatory Approvals and Market Expansion: Vutrisiran has received approvals from major regulatory bodies, including the U.S. FDA and the European Medicines Agency, facilitating its availability across multiple regions. This has expanded the market reach and accessibility of the drug.

Favorable Market Projections: The global vutrisiran market was valued at approximately USD 600 million in 2022 and is projected to reach around USD 2,087 million by 2033, exhibiting a compound annual growth rate (CAGR) of 12% during the forecast period.

Strategic Collaborations: Partnerships, such as the collaboration between Alnylam Pharmaceuticals and AstraZeneca, have bolstered the development and commercialization efforts for vutrisiran, enhancing its market presence and potential.

Competitive Landscape: While vutrisiran faces competition from other treatments like Pfizer's Vyndaqel and BridgeBio Pharma's acoramidis, its unique mechanism of action and positive clinical trial outcomes position it as a strong contender in the market.

Read More Details - https://www.marketresearchfuture.com/reports/vutrisiran-market-33305

𝖮𝗍𝗁𝖾𝗋 𝖫𝖺𝗍𝖾𝗌𝗍 𝖧𝖾𝖺𝗅𝗍𝗁𝖼𝖺𝗋𝖾 𝖳𝗋𝖾𝗇𝖽𝗂𝗇𝗀 𝖨𝗇𝗌𝗂𝗀𝗁𝗍𝗌

Upper Limb Prosthetic Market: https://www.marketresearchfuture.com/reports/upper-limb-prosthetic-market-42768

Urea Cycle Disorder Market: https://www.marketresearchfuture.com/reports/urea-cycle-disorder-market-42191

Ureteral Dilators Market: https://www.marketresearchfuture.com/reports/ureteral-dilators-market-41279

Urodynamic Equipment Market: https://www.marketresearchfuture.com/reports/urodynamic-equipment-market-27098

Ustekinumab Market: https://www.marketresearchfuture.com/reports/ustekinumab-market-39614

UV Spectroscopy Market: https://www.marketresearchfuture.com/reports/uv-spectroscopy-market-42197

Vaccine Delivery Device Market: https://www.marketresearchfuture.com/reports/vaccine-delivery-device-market-42198

Vaccine Research Market: https://www.marketresearchfuture.com/reports/vaccine-research-market-27935

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Market Research Future
Market Research Future
+1 855-661-4441
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next